Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy

SUMMARY: Fabry’s disease is an X-linked lysosomal storage disease most often associated with renal dysfunction and death due to renal failure in patients’ fourth and fifth decades of life. However, cardiac manifestations including arrhythmias, angina and heart failure are common and probably under-recognised. Furthermore, Fabry’s disease is now recognised as also affecting female carriers, who manifest signs later than males. A variant of Fabry’s has been identified that only affects cardiac tissue, which presents as an unexplained hypertrophy of the left ventricle in middle-aged patients, possibly with women more affected than men. Given that epidemiological studies report a prevalence of Fabry’s cardiomyopathy among middle-aged patients with cardiac hypertrophy to be anywhere from one to 12%, it is reasonable to screen these patients for alpha-galactosidase A deficiency. Although mortality data is lacking from randomised, controlled trials of galactosidase replacement therapy, there are some reports of improvement in cardiac endpoints. Therefore patients with known Fabry’s disease should be screened early for cardiac involvement, as treatment benefit may not be seen once cardiac fibrosis has developed.